The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Phase 1 results of ABBV-400, a c-Met-targeting ADC, in advanced G/GEJA
John Strickler, MD, Duke Cancer Institute, Durham, NC, discusses findings from a Phase I study (NCT05029882) of ABBV-400, a c-Met–targeting antibody-drug conjugate (ADC) for advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA). ABBV-400 had some promising antitumor activity and a manageable safety profile, and common treatment-emergent adverse events (TEAEs) included anemia, nausea, and thrombocytopenia. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
